Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
RPG Life Sciences Limited (RPGLIFE.NS)
INR2,978.10
+237.90 (+8.68%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
RPG HOUSE 400030
Mumbai, IN
Mumbai, IN
CEO
Ashok Nair
Website
rpglifesciences.com
IPO
2002-08-12
ISIN INE105J01010
Also trades on
Bombay Stock Exchange · RPGLIFE.BO (INR)
National Stock Exchange of India · RPGLIFE.NS (INR)
Description
RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs) for both the Indian and global markets. The company provides synthetic APIs for diverse medical applications, including immunosuppression, psychiatric conditions, cardiac health (anti-anginals), parasitic infections (anthelmentics), seizure management (anticonvulsants), and muscle spasm relief (antispasmodics). While its generics portfolio primarily centers on immunosuppressant treatments, its finished dosage formulations address a wide spectrum of therapeutic areas, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular health, diabetology, orthopedics, neuropsychiatry, and respiratory conditions, among many others. Established in 1968 with its headquarters in Mumbai, India, the company adopted its current name in February 2008, having previously been known as RPG Pharmaceuticals Limited. RPG Life Sciences Limited functions as a subsidiary of Nucleus Life Trust.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR2,978.10
+237.90 (+8.68%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
46.0K
Beta
-0.21
Float Shares
3.97M
Free Float %
24.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.78% | +2.87% | -4.99% | +17.85% | -4.30% | -4.55% | -5.33% | +141.33% | +367.26% | +816.18% | +6,647.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,978.10
DCF (Unlevered)
3,415.52
+14.7%
DCF (Levered)
2,694.95
-9.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
13.80
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+8.3% ★ Q1'26: +23.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-37.2% Q1'26: -74.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.0% Q1'26: -11.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+17.8% ★ Q1'26: +15.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+26.8% ★ Q1'26: +23.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.14× ★ Q1'26: 0.15× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2011 actual |
Mar 2012 actual |
Mar 2015 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.84B
est: 1.95B (-5.4%)
|
1.93B
est: 2.11B (-8.4%)
|
2.42B
est: 2.98B (-18.6%)
|
3.06B
est: 3.04B (+0.7%)
|
3.37B
est: 3.49B (-3.4%)
|
3.24B
est: 3.04B (+6.5%)
|
3.69B
est: 3.49B (+5.8%)
|
3.83B
est: 4.22B (-9.0%)
|
4.37B
est: 3.70B (+18.2%)
|
5.09B
est: 4.13B (+23.2%)
|
5.77B
est: 4.63B (+24.8%)
|
6.53B
est: 3.04B (+114.8%)
|
3.04B
3.04B – 3.04B
+0.0% YoY
|
3.49B
3.49B – 3.49B
+14.7% YoY
|
4.22B
4.22B – 4.22B
+20.8% YoY
|
3.70B
3.70B – 3.70B
-12.2% YoY
|
4.13B
4.13B – 4.13B
+11.7% YoY
|
4.63B
4.63B – 4.63B
+12.0% YoY
|
| EBITDA |
327.70M
est: 423.46M (-22.6%)
|
188.40M
est: 448.86M (-58.0%)
|
141.70M
est: 646.99M (-78.1%)
|
294.90M
est: 661.35M (-55.4%)
|
394.20M
est: 758.53M (-48.0%)
|
343.60M
est: 661.35M (-48.0%)
|
555.70M
est: 758.53M (-26.7%)
|
718.40M
est: 916.37M (-21.6%)
|
902.40M
est: 725.58M (+24.4%)
|
1.08B
est: 723.44M (+49.7%)
|
1.36B
est: 1.44B (-5.1%)
|
1.60B
est: 685.55M (+132.9%)
|
685.55M
685.55M – 685.55M
+0.0% YoY
|
786.28M
786.28M – 786.28M
+14.7% YoY
|
949.89M
949.89M – 949.89M
+20.8% YoY
|
833.71M
833.71M – 833.71M
-12.2% YoY
|
931.02M
931.02M – 931.02M
+11.7% YoY
|
1.04B
1.04B – 1.04B
+12.0% YoY
|
| EBIT |
232.45M
est: 356.62M (-34.8%)
|
86.00M
est: 378.01M (-77.2%)
|
28.10M
est: 544.87M (-94.8%)
|
181.80M
est: 556.96M (-67.4%)
|
241.60M
est: 638.80M (-62.2%)
|
190.40M
est: 556.96M (-65.8%)
|
382.00M
est: 398.71M (-4.2%)
|
553.70M
est: 771.72M (-28.3%)
|
745.80M
est: 677.33M (+10.1%)
|
928.30M
est: 525.66M (+76.6%)
|
1.19B
est: 1.34B (-10.9%)
|
1.38B
est: 605.66M (+128.2%)
|
605.66M
605.66M – 605.66M
+0.0% YoY
|
694.65M
694.65M – 694.65M
+14.7% YoY
|
839.20M
839.20M – 839.20M
+20.8% YoY
|
736.56M
736.56M – 736.56M
-12.2% YoY
|
822.53M
822.53M – 822.53M
+11.7% YoY
|
921.23M
921.23M – 921.23M
+12.0% YoY
|
| Net Income |
127.12M
est: 131.58M (-3.4%)
|
8.50M
est: 105.75M (-92.0%)
|
10.00M
est: 745.53M (-98.7%)
|
204.60M
est: 157.28M (+30.1%)
|
134.50M
est: 247.08M (-45.6%)
|
108.10M
est: 157.28M (-31.3%)
|
290.10M
est: 247.08M (+17.4%)
|
400.00M
est: 391.62M (+2.1%)
|
514.80M
est: 324.31M (+58.7%)
|
676.40M
est: 405.78M (+66.7%)
|
876.60M
est: 429.16M (+104.3%)
|
1.83B
est: 157.28M (+1,065.1%)
|
157.28M
157.28M – 157.28M
+0.0% YoY
|
247.08M
247.08M – 247.08M
+57.1% YoY
|
391.62M
391.62M – 391.62M
+58.5% YoY
|
324.31M
324.31M – 324.31M
-17.2% YoY
|
375.25M
375.25M – 375.25M
+15.7% YoY
|
429.16M
429.16M – 429.16M
+14.4% YoY
|
| SGA |
—
est: 507.64M (-100.0%)
|
—
est: 538.09M (-100.0%)
|
686.30M
est: 775.60M (-11.5%)
|
253.40M
est: 792.82M (-68.0%)
|
304.60M
est: 909.31M (-66.5%)
|
281.10M
est: 792.82M (-64.5%)
|
329.70M
est: 1.38B (-76.1%)
|
1.05B
est: 1.10B (-4.0%)
|
1.15B
est: 964.17M (+19.6%)
|
1.35B
est: 2.25B (-40.2%)
|
1.54B
est: 1.21B (+27.9%)
|
1.52B
est: 768.95M (+98.0%)
|
768.95M
768.95M – 768.95M
+0.0% YoY
|
881.94M
881.94M – 881.94M
+14.7% YoY
|
1.07B
1.07B – 1.07B
+20.8% YoY
|
935.14M
935.14M – 935.14M
-12.2% YoY
|
1.04B
1.04B – 1.04B
+11.7% YoY
|
1.17B
1.17B – 1.17B
+12.0% YoY
|
| EPS |
7.69
est: 7.96 (-3.3%)
|
0.51
est: 6.43 (-92.1%)
|
0.60
est: 45.08 (-98.7%)
|
12.70
est: 9.51 (+33.5%)
|
8.13
est: 14.94 (-45.6%)
|
6.54
est: 9.51 (-31.2%)
|
17.54
est: 14.94 (+17.4%)
|
24.19
est: 23.68 (+2.2%)
|
31.13
est: 19.61 (+58.7%)
|
40.90
est: 22.69 (+80.3%)
|
53.00
est: 25.95 (+104.2%)
|
110.80
est: 9.51 (+1,065.1%)
|
9.51
9.51 – 9.51
+0.0% YoY
|
14.94
14.94 – 14.94
+57.1% YoY
|
23.68
23.68 – 23.68
+58.5% YoY
|
19.61
19.61 – 19.61
-17.2% YoY
|
22.69
22.69 – 22.69
+15.7% YoY
|
25.95
25.95 – 25.95
+14.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-10 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-09 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-03 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-02 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-01 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
147.08M
OE per share TTM
8.90
Owner's Yield
0.40%
Maintenance CapEx ratio
3.49%
Maint CapEx / Avg PPE
26.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
989.1K
Shares Outstanding
16.54M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amol Narayan Lone | Chief Financial Officer | — | male |
| Ashok Nair | MD & Additional Director | — | male |
| Deepak Shukla | Chief Executive of API Business | — | male |
| Kartick C. Patra | Head of API Operations & Procurement | — | male |
| Milind Gujar | Chief Quality Officer | — | male |
| Rajesh Chopra | Site Head of International Formulation | — | male |
| Rajesh Shirambekar | Head of Legal, Compliance Officer & Company Secretary | — | male |
| Samir Rane | Vice President of Sales & Marketing (Main Division) | — | male |
| Sheetal Gaba | Chief Human Resources Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RPGLIFE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
